
Wall Teichoic Acids of Gram-Positive Bacteria

Stephanie Brown, John P. Santa Maria Jr., and Suzanne Walker

Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts 02115; email: suzanne_walker@hms.harvard.edu

---

### Keywords
peptidoglycan, bacterial cell wall, D-alanylation, MRSA, virulence factor, biofilm

---

### Abstract
The peptidoglycan layers of many gram-positive bacteria are densely functionalized with anionic glycopolymers known as wall teichoic acids (WTAs). These polymers play crucial roles in cell shape determination, regulation of cell division, and other fundamental aspects of gram-positive bacterial physiology. Additionally, WTAs are important in pathogenesis and play key roles in antibiotic resistance. We provide an overview of WTA structure and biosynthesis, review recent studies on the biological roles of these polymers, and highlight remaining questions. We also discuss prospects for exploiting WTA biosynthesis as a target for new therapies to overcome resistant infections.

# Contents

INTRODUCTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1

Teichoic acid polymers are located within the gram-positive cell wall. This schematic of the gram-positive cell wall shows that WTAs are covalently anchored to PG and LTAs are tethered to the membrane. The WTAs extend beyond the PG layer, whereas fully extended LTAs may not be able to reach past the PG layer. Abbreviations: LTA, lipoteichoic acid; PG, peptidoglycan; WTA, wall teichoic acid.

## TEICHOIC ACID DEFINITION

Armstrong et al. (6) discovered teichoic acids in 1958 while trying to determine the function of CDP-glycerol and CDP-ribitol in *Lactobacillus arabinosus*, *Bacillus subtilis*, and several other bacteria. The term teichoic acid encompasses a diverse family of cell surface glycopolymers containing phosphodiester-linked polyol repeat units (133). Teichoic acids include both lipoteichoic acids (LTAs), which are anchored in the bacterial membrane via a glycolipid, and WTAs, which are covalently attached to PG (91, 133) (Figure 1). This article focuses primarily on WTAs. For information on LTAs the reader is directed to a recent review by Reichmann & Gründling (106).

## WALL TEICHOIC ACID BACKBONE STRUCTURE

WTAs are highly abundant modifications of gram-positive cell walls (90). In *B. subtilis* and *S. aureus*, it has been estimated that every ninth PG N-acetylmuramic acid (MurNAc) residue possesses an attached WTA polymer containing 40 to 60 polyol repeats (12, 71). The total mass of WTAs in these and other organisms constitutes up to 60% of the cell wall (44, 124). Cryo-electron microscopy images suggest that, consistent with their estimated length, *S. aureus* WTAs extend well beyond the PG layer (81, 82, 106).

The WTA polymer can be divided into two components: a disaccharide linkage unit and a main chain polymer composed of phosphodiester-linked polyol repeat units (91) (Figure 2). The disaccharide linkage unit, which is highly conserved across bacterial species, is composed of N-acetylmannosamine (β1→4) N-acetylglucosamine 1-phosphate [ManNAc(β1→4)GlcNAc-1P] with one to two glycerol 3-phosphate units attached to the C4 oxygen of ManNAc (5, 71, 91).

a

Linkage unit

![Image of linkage unit](image1.png)

b

Repeat units

Type I
poly(polyol phosphate)

![Image of Type I structure](image2.png)
GroP  
$X = \text{D-alanine or } \alpha\text{-glucose}$

Type II
poly(glycosylpolyol phosphate)

![Image of Type II structure](image3.png)
RboP  
$X = \text{D-alanine}$  
$Y = \alpha\text{- or } \beta\text{-GlcNAc/glucose}$

GlcNAc-RboP  
$X = \text{Galactose}$  
$Y = \beta\text{-Glucose}$

(GalNAc)₂-RboP

Type III
poly(glycosyl phosphate–polyol phosphate)

![Image of Type III structure](image4.png)
GlcNAc-P-RboP

Type IV
poly(polyol phosphate–glycosylpolyol phosphate)

![Image of Type IV structure](image5.png)
RboP-GalNAc-RboP

Figure 2

WTA polymers share a common linkage unit but exhibit structural diversity in their repeat units. (a) The commonly characterized WTA linkage unit consists of a GroP-ManNAc-GlcNAc-P that is covalently attached to peptidoglycan. Although the stereochemistry of the glycosidic linkage has not been clearly established, it is assumed to be retained as $\alpha$ on the basis of predicted enzymatic catalysis. (b) Four different classes of WTA repeat units found in gram-positive bacteria (90). Abbreviations: GalNAc, $N$-acetylgalactosamine; GlcNAc, $N$-acetylglucosamine; GroP, glycerol 3-phosphate; ManNAc, $N$-acetylmannosamine; MurNAc, $N$-acetylmuramic acid; P, phosphate; RboP, ribitol 5-phosphate; WTA, wall teichoic acid.

The anomeric phosphate of the linkage unit is covalently attached to PG via a phosphodiester bond to the C6 hydroxyl of MurNAc. The phosphodiester-linked polyol repeats extend from the GroP end of the linkage unit (91, 133).

The best-characterized WTA structures contain repeat units of ribitol 5-phosphate (RboP) or glycerol 3-phosphate (GroP), but WTA monomer structures can be highly diverse, and many published structures are more unusual (45, 46, 90). Other WTA repeat units include variations of glycosylpolyol phosphate or glycosyl phosphate–polyol phosphate (90, 91) (Figure 2). WTA structural diversity can exist within the same species, as in *B. subtilis*, in which strains 168 and W23 contain GroP and RboP repeat units, respectively. *Lactobacillus plantarum* has the ability to switch backbone composition (21). Furthermore, single strains of *S. aureus* and *Bacillus coagulans* can contain polymers with distinct repeats expressed simultaneously but at different levels.
(102, 128). WTA structural variations may represent adaptations to different environments. Relatedly, bacteria are known to modulate transcription of WTA biosynthetic genes in response to stress conditions (87). Despite their diversity, all WTAs contain a negatively charged anionic backbone and share common functions.

### TAILORING MODIFICATIONS ON THE WALL TEICHOIC ACID POLYMER

Additional WTA structural diversity arises from the presence or absence of substituents attached to the repeating monomers (Figure 3). The repeat unit hydroxyls can be tailored with cationic D-alanine esters or a variety of mono- or oligosaccharides, commonly glucose or GlcNAc (91). In RboP polymers, D-alanyl residues are installed at position 2 of ribitol and sugars are commonly found at position 4 (91, 128). D-Alanine ester content is variable and depends on several factors, including pH, salt concentration, and temperature (64, 91). In contrast, the WTA sugar substituents do not appear to fluctuate with changes in the cellular environment (32). These tailoring modifications are typically highly abundant. For example, nearly all of the RboP repeats in *S. aureus* contain O-GlcNAc substituents (64). Depending on the bacterial strain, the anomeric configuration of the glycosidic linkage to the repeat unit can be exclusively α, exclusively β, or a mixture of the two (29, 45, 46, 88). Some *S. aureus* strains have been found to contain, in the same cell wall, two different poly(RboP) WTAs, one fully α-glycosylated and the other fully β-glycosylated (125). In *B. subtilis* W23 it was observed that some WTA strands were fully glycosylated, whereas other strands contained no sugar substituents (29).

### WALL TEICHOIC ACID BIOSYNTHESIS

#### Overview

Much of the early work to understand WTA biosynthesis used particulate enzyme preparations. Though this work enabled characterization of the enzymatic steps in WTA polymer formation, the identities of the enzymes responsible for these steps remained elusive (133). Later, genetic analyses of temperature-sensitive and phage-resistant mutants led to the identification of the poly(GroP) WTA gene cluster in *B. subtilis* 168 and the poly(RboP) WTA gene cluster in *B. subtilis* W23 (65, 148). Sequence analysis led to proposals for the enzymatic activity encoded by each gene (75, 91, 133). However, it proved challenging to fully characterize the pathway using genetics because many of the biosynthetic genes are essential (14, 15, 36, 38, 69). Efforts to characterize WTA enzymes biochemically were hampered because the substrates contain 55-carbon lipid chains that make them difficult to handle. Moreover, these lipid-linked substrates are present in very low abundance and cannot be isolated in useful quantities from bacterial cells. The development of chemoenzymatic methods to make WTA substrates has not only allowed elucidation of biosynthetic pathways but also permitted mechanistic studies on purified teichoic acid enzymes in the absence of membranes (22, 24, 54, 110, 113, 150).

#### Linkage Unit Synthesis

In 1978 Archibald and colleagues used electron microscopy to show that WTA synthesis begins in the cytoplasm at the wall-membrane interface and that the WTA polymer subsequently appears on the outer surface of the cell (3, 133). TagO catalyzes the first synthetic step: the transfer of GlcNAc-1-P from UDP-GlcNAc to a membrane-anchored undecaprenyl phosphate carrier

**GlcNAc:**  
N-acetylglucosamine  

**Poly(RboP):**  
poly(ribitol 5-phosphate)  

**Poly(GroP):**  
poly(glycerol 3-phosphate)  
**Figure 3**

In different organisms, WTA biosynthesis begins with the same initial steps but then the pathways diverge.

(a) The initial steps to WTA polymer formation that have been found in all pathways characterized thus far.

(b–d) The end-stage intracellular steps to form the WTA polymer in (b) *Bacillus subtilis* 168, (c) *B. subtilis* W23, and (d) *Staphylococcus aureus*. TarIJ reactions to form CDP-ribitol exist in both *B. subtilis* W23 and *S. aureus*. The α or β within the sugar denotes the stereochemistry of attachment. We have shown α- and β-GlcNAc attachment to *S. aureus* occurring on the same strand, but it is possible that the TarS and TarM enzymes do not attach GlcNAc to the same polymer. Abbreviations: GlcNAc, N-acetylglucosamine; ManNAc, N-acetylmannosamine; WTA, wall teichoic acid.

lipid, an intermediate shared with PG biosynthesis (107, 116). The TagO product is used in the synthesis of several *B. subtilis* 168 cell wall polymers, including the major WTA [poly(GroP)], the minor teichoic acid (TA) [poly(glucosyl N-acetylgalactosamine 1-phosphate)], and teichuronic acid [poly(glucuronyl N-acetylgalactosamine)] (116). Consequently, the first committed step in WTA biosynthesis is the transfer of ManNAc from UDP-ManNAc to the C4 hydroxyl of GlcNAc to form the ManNAc(β1→4)GlcNAc disaccharide, catalyzed by TarA (35, 54, 150). The

UDP-ManNAc donor sugar is derived from UDP-GlcNAc via MnaA ($yvyH$), an epimerase that catalyzes stereochemical inversion at the C2 position (117). TagB, a glycerophosphotransferase, catalyzes the transfer of a GroP unit from CDP-glycerol to the C4 position of ManNAc (16, 54). These first three steps to complete the synthesis of the WTA linkage unit are highly conserved across all strains characterized thus far (Figure 3). After these steps, WTA pathways diverge.

**Poly(Glycerol 3-Phosphate) Wall Teichoic Acid Synthesis**

The genes encoding proteins involved in poly(GroP) WTA synthesis are annotated as $tag$ genes (teichoic acid glycerol) (19). $B$. subtilis 168 is the most studied of the poly(GroP) WTA-producing organisms (Figure 3). After the action of TagO, TagA, and TagB to complete synthesis of the linkage unit, TagF adds 45–60 GroP units to the TagB product to assemble the polymer (78, 98, 109, 110, 113). The GroP moiety originates from the activated precursor CDP-glycerol, which is synthesized by TagD, a cytidylyltransferase that catalyzes the transfer of L-$\alpha$-glycerol 3-phosphate to CTP, releasing pyrophosphate (94). Although the Tag enzymes from $B$. subtilis 168 remain the most characterized of the poly(GroP) WTA biosynthetic enzymes, homologs have been identified and loosely characterized in other bacteria known to contain poly(GroP) WTAs, including *Enterococcus faecalis*, *L*. *plantarum*, *Staphylococcus epidermidis*, and several species of *Streptomyces* (33, 39, 50, 86, 89).

In 2010, Strynadka and colleagues (78) published the first and so far only crystal structure of a teichoic acid enzyme involved in polymer synthesis. The structure showed that $S$. *epidermidis* TagF possesses a GT-B glycosyltransferase fold and an extended open active site that appears capable of accommodating the rebinding of CDP-glycerol without product release. Whereas this observation suggests a processive mechanism, kinetic studies found that polymer length depended on the ratio of CDP-glycerol to lipid acceptor, supporting a distributive mechanism (98, 110, 113). The crystal structure of TagF should allow for further mechanistic studies on this class of phosphotransferases. TagB and TagF share 50% similarity in their catalytic domains, but features governing primase versus polymerase activity await identification.

**Poly(Ribitol 5-Phosphate) Wall Teichoic Acid Synthesis**

Enzymes making poly(RboP) WTAs are designated Tar for teichoic acid ribitol (19), but it should be noted that TarO, TarA, TarB, and TarD have the same biochemical functions as TagO, TagA, TagB, and TagD, respectively. In $S$. *aureus*, following formation of the lipid-PP-ManNAc-GlcNAc-GroP product by TarO, TarA, and TarB, poly(RboP) synthesis continues with the TarF-mediated transfer of a (predominantly) single unit of GroP from CDP-glycerol, synthesized by TarD (9, 22, 24, 85, 135). As described above, the synthesis of poly(GroP) WTAs requires a GroP primase (TagB) as well as a GroP polymerase (TagF), and it was proposed that poly(RboP) WTA synthesis in $S$. *aureus* requires both a RboP primase and a RboP polymerase to make the main chain polymer (75, 105). Recent work has shown, however, that $S$. *aureus* contains a single enzyme, TarL, that primes the linkage unit and then attaches more than 40 RboP units to complete the polymer (24, 85, 97) (Figure 3). The CDP-ribitol substrate utilized by TarL is made by the combined action of TarI, a cytidylyltransferase, and TarJ, an alcohol dehydrogenase (96, 151). All $S$. *aureus* strains contain two sets of $tarIJL$ genes (the second set is designated $tarI'J'K'$) (105). The significance of these duplications is still unclear (85, 97, 105, 120, 144).

Whereas poly(GroP) WTA biosynthesis has been fully characterized in only one organism, $B$. subtilis 168, poly(RboP) WTA biosynthesis has been characterized in both $B$. *subtilis* W23 and $S$. *aureus* (22, 24) (Figure 3). These two organisms produce very similar poly(RboP) WTAs, which
differ only in the number of GroP repeats in the linkage unit (one versus two) and in the sugar tailoring modifications (the addition of Glc versus GlcNAc) (91, 147). Both organisms appear to contain the same *tar* genes (75, 105), but their WTA biosynthetic pathways differ. Although *S. aureus* uses a single enzyme to prime the linkage unit and build the RboP polymer chain, *B. subtilis* W23 requires an RboP primase, TarK (22, 85). Furthermore, TarK acts directly on the TagB product. Thus, *B. subtilis* W23 does not require the enzymatic activity of TarF even though it contains a *tarF* gene. In *S. aureus* *tarF* is essential, but genetic analysis has established that *B. subtilis* *tarF* is neither essential nor transcribed under laboratory culture conditions (22). The WTA polymer in *B. subtilis* W23 is completed by the RboP polymerase TarL, which can attach upward of 40 RboP units (147). Thus, *B. subtilis* W23 TarL is not a bifunctional primase-polymerase like its *S. aureus* homolog but can utilize only WTA lipid-linked substrates that are primed with RboP by TarK (22, 85).

The biochemical and genetic studies of WTA biosynthesis described above have substantially expanded our understanding of how WTA polymers are made, but they also highlight challenges in predicting enzymatic pathways from genome sequences. Other pathways will most likely begin with the same initial steps but may then diverge (Figure 2). In principle, the presence of *tagD* and *tarIJ* genes, required to make CDP-glycerol (*tagD*) and CDP-ribitol (*tarIJ*) substrates, should facilitate prediction of WTA polymer composition (11, 39, 124). It should be noted, however, that strains containing both types of genes may produce only one type of polymer. For example, some strains of *L. plantarum* that make only poly(GroP) polymers contain both *tarIJKL* and *tagDF* homologs, but the *tarIJ* gene homologs are not transcribed (21, 124). More perplexing is a recent report of an *E. faecalis* strain that makes a WTA poly(RboP) polymer but does not have a *tarJ* homolog (122).

## Attachment of Sugars to the Polyol Chain

Data suggest WTA glycosylation occurs inside the cell after polymer synthesis is complete prior to WTA export to the cell surface (1, 23). In the past few years several WTA glycosyltransferases have been identified. In *B. subtilis* 168, TagE modifies WTAs with α-glucose using UDP-glucose as a donor substrate (1, 10). In *B. subtilis* W23, TarQ attaches β-glucose units to poly(RboP) WTAs (23). In *S. aureus*, RboP WTA α-O-GlcNAc modifications are installed by TarM (145) and β-O-GlcNAc modifications are installed by TarS (23). As mentioned above, WTAs extracted from cells appear to be heavily modified with sugars of the same stereochemistry or not modified at all (29, 45, 46, 125), suggesting that the glycosyltransferases are processive enzymes that fully glycosylate WTAs. Processivity may ensure that individual polymers are densely modified and, in organisms that contain more than one glycosyltransferase, may also prevent the attachment of sugars of different stereochemistries to the same polymer. The presence or absence of sugars and the glycosidic linkage conformation affect polymer structure and likely influence interactions with other components in the cell envelope or at the cell interface (13). Strains lacking modifications have altered phenotypes with regard to antibiotic susceptibility and virulence (23, 144). Although progress has been made with regard to the roles of the WTA sugar substituents, numerous questions remain.

## Polymer Export

The final steps in the WTA biosynthetic pathway, those following polymer formation and sugar tailoring, are not as clearly defined as are earlier steps. For both poly(GroP) and poly(RboP) WTA polymers, the polymer is translocated through the membrane by a two-component ABC (ATP-binding cassette) transporter (TagGH and TarGH, respectively) (76). TagH, containing an ATPase domain, provides energy to drive a conformational change in the transmembrane
Figure 4

WTA polymer flipping and attachment to PG in *Bacillus subtilis* 168 proceeds through a series of enzymes. In this schematic, the poly(GroP) WTA polymer in *B. subtilis* 168 is transported through the cell membrane by TagGH. Homology suggests that energy generated by TagH ATP hydrolysis drives a conformational change that allows for polymer transport. TagGH can presumably either (a) thread the polymer through the membrane by the nonreducing end or (b) recognize the disaccharide linkage unit and flip the polymer across. (c) Following transport, the polymer is covalently attached to PG by TagTUV. It is unknown whether the TagTUV enzymes work independently or together to ligate WTA to PG. The energy source for this ligation reaction, which we designated here as ATP hydrolysis, is undetermined. It remains unknown whether extracellular D-alanylation by DltABCD occurs before or after WTA is covalently attached to PG.

Abbreviations: GroP, glycerol 3-phosphate; PG, peptidoglycan; WTA, wall teichoic acid.

component, TagG, which somehow facilitates translocation across the membrane (76, 111). The WTA transporter exports polymers containing main chains that can be more than ten times longer than the width of the lipid bilayer. In principle, there are two models for how export may occur: One involves a threading mechanism in which the polymer is fed through the transporter from the nonreducing end, eventually pulling the linkage unit across; the other involves a flipping mechanism in which the lipid-PP-GlcNAc-ManNAc linkage unit is somehow flipped across the membrane, with the polymer chain following (Figure 4). The former model is conceptually

simpler, but experimental studies support the latter model in that they show the linkage unit, and not the main chain, is recognized by TagGH (21, 111). It is not known whether translocation occurs concomitantly with or following polymerization. Reconstitution of the translocation process in proteoliposomes would provide valuable mechanistic insight and may be possible now that all previous steps have been characterized and enzymes to make the precursors are available.

## Wall Teichoic Acid Attachment to Peptidoglycan

Once the polymer is outside the cell, the final stage of WTA biosynthesis is the formation of a phosphodiester linkage between the WTA polymer and the C6 hydroxyl of the PG MurNAc unit. On the basis of genetic evidence, a set of redundant enzymes, TagTUV, was recently proposed to be responsible for catalyzing this coupling reaction in *B. subtilis* 168 (66), and similar evidence supports a related function for three homologous enzymes in *S. aureus* (40, 62, 92) (Figure 4). TagT has geranyl pyrophosphatase activity (42, 66), which is presumed to be a surrogate for attack of the WTA phosphodiester bond by the C6 MurNAc hydroxyl of PG, but an authentic coupling reaction must be reconstituted to confirm the proposed WTA ligase activity.

The question of when and where WTAs are synthesized and attached to PG is still debated. Decades ago, some studies suggested the WTA polymer is attached to nascent (new) PG, whereas others indicated that it may be attached to mature (old) PG. Still others suggested it can be attached to concurrently synthesized as well as preexisting PG (20, 83, 123, 133, 141). Recently, the timing and location of WTA synthesis has been revisited. In cryo-electron microscopy images, Matias & Beveridge (80–82) identified densely staining material at the septa of *B. subtilis* and *S. aureus* as WTAs and proposed that WTAs are attached to new PG during cell division. Consistent with this hypothesis, this densely staining material disappears in a time-dependent fashion when the first step in WTA synthesis is inhibited (25). Furthermore, studies using fluorescent protein fusions show that WTA biosynthetic proteins localize predominantly to the septum in *B. subtilis* and *S. aureus* (7, 16, 51), suggesting that WTAs are attached to nascent PG during cell division (septum formation). However, other studies suggest that WTAs are attached to older PG (4, 112). Fluorescently labeled concanavalin A, a lectin reported to bind to α-GlcNAcylated WTAs, was used to probe the location of WTAs in *S. aureus*. Fluorescent concanavalin A bound to the half of the cell containing old PG but not to the half containing PG produced during cross wall formation (cell division) (4, 112). Additional studies using alternative detection methods are required to resolve the location of WTA attachment.

## D-Alanylation of the Wall Teichoic Acid Repeat Unit

Attachment of D-alanine esters to WTAs is an important mechanism by which bacteria modulate surface charge (32). Unlike glycosylation, which occurs inside the cell, D-alanylation occurs following export of WTAs to the cell surface. Four enzymes, encoded by the *dltABCD* operon, attach D-alanines to both LTAs and WTAs (72, 84, 95) (Figure 5). DltA resembles the adenylation domains of nonribosomal peptide synthetases. It is responsible for activating D-alanine as an AMP ester (58) and then transferring the aminoacyl adenylate to DltC. DltC possesses a pantothenate cofactor that forms a thioester with D-alanine through nucleophilic attack of the sulfhydryl on the mixed anhydride (59, 129). What happens after DltC is charged with D-alanine is unclear, but it involves both DltB and DltD (Figure 5). DltB, which contains several predicted membrane-spanning helices, is an uncharacterized membrane protein of the membrane-bound O-acetyltransferase (MBOAT) family. DltD is a membrane-anchored protein predicted to have a short intracellular N terminus and a large extracellular C-terminal domain with predicted esterase/thioesterase activity. DltD was shown to hydrolyze D-alanine from acyl carrier protein,

MI67CH15-Walker ARI 5 August 2013 17:19

![Diagram](attachment://image.png)

Figure 5  
D-alanylation of teichoic acids. The DltABCD machinery is responsible for the activation and attachment of D-alanines to extracellular teichoic acids. Many questions remain regarding the roles of DltB and DltD, the nature of their substrates, and whether D-alanine transesterification is enzymatically catalyzed.

Abbreviations: GlcNAc, N-acetylglucosamine; LTA, lipoteichoic acid; ManNAc, N-acetylmannosamine; WTA, wall teichoic acid.

which is normally involved in fatty acid biosynthesis; on this basis DltD was suggested to have an editing function and to remove D-alanine from mischarged acyl carrier protein (34). It was also shown to modestly accelerate the rate of transfer of D-alanine to DltC, suggesting an accessory role in the transfer reaction (34). These proposals for DltD require it to function in the cytoplasm, which is inconsistent with its predicted topology. At this point, the specific function of DltD is unclear.

It has been proposed on the basis of pulse-chase experiments that D-alanines are transferred to LTAs by DltC and then to WTAs in an isoenthalpic transesterification reaction (56). Supporting such a mechanism, D-alanyl esters can be transferred between LTAs of differing lengths in nonnative micelles without an enzyme catalyst, though the reaction is slow (28). Alternatively, D-alanyl esters could be transferred back from LTAs to DltC and then to WTAs (68). Because this transfer reaction requires bacterial membranes, other factors may also play a role in the process. DltB is also required for D-alanylation, and it has been suggested to facilitate membrane translocation of D-alanine-charged DltC so that it can serve as the direct donor to LTA (91). DltC has not been identified in any proteomic analyses of secreted proteins, and the evidence that it serves as the direct D-alanylation donor is limited (41, 68, 91). Although it is clear that D-alanylation of LTAs and WTAs requires the same biosynthetic machinery, many questions remain regarding the enzymology of the process.

**NONESSENTIAL AND CONDITIONALLY ESSENTIAL WALL TEICHOIC ACID GENES**

Deletion of *tagO* or *tagA*, the first two genes in the WTA biosynthetic pathway, produces bacteria lacking WTA polymers. These bacteria display a range of defects, but are viable in traditional

www.annualreviews.org • WTAs of Gram-Positive Bacteria
laboratory conditions. With the exception of the tailoring enzymes, however, most of the downstream WTA genes are essential, and their deletion results in a lethal phenotype unless flux into the WTA pathway is blocked at an early stage (36, 38). The lethality of a late-stage block may be due to accumulation of toxic intermediates in the cell or to depletion of cellular pools of undecaprenyl phosphate, which is also required for the synthesis of PG (36–38, 120, 144). Conditionally essential genes are found in pathways for other cell wall polysaccharides that are synthesized on the undecaprenyl phosphate carrier lipid. For example, deletion of late-stage genes involved in synthesis of the capsular polysaccharide of *Streptococcus pneumoniae* generates bacteria with suppressor mutations in the initiating enzyme that turns off capsule production (63, 142).

### ROLES OF WALL TEICHOIC ACIDS

WTA polymers play numerous, varied roles in the cell wall owing to their location, abundance, and polyanionic nature. The molecular mechanisms underlying their many critical functions are not well understood. Genetic and small molecule tools are enabling more detailed studies to elucidate these mechanisms.

#### Regulation of Cell Morphology and Division

Bacteria lacking WTAs grow slower than wild-type bacteria, and they clump in solution. These strains exhibit numerous morphological abnormalities, including a nonuniform thickening of the PG cell wall, increased cell size, and defects in septal positioning and number (4, 25, 31, 36, 93, 112). Furthermore, rod-shaped bacteria such as *B. subtilis* and *Listeria monocytogenes* lose their shape, becoming spherical (14, 19, 43, 47, 116, 117). These phenotypes imply that WTAs are necessary for proper localization, assembly, and/or activation of cell wall elongation and division machinery. Consistent with this idea, many WTA and PG biosynthetic enzymes have been shown to colocalize and physically interact in *B. subtilis* (51, 66).

Evidence for functional interactions between WTAs and PG machinery comes from *S. aureus*, in which the putative PG cross-linking enzymes PBP4 and FmtA lose septal localization in the absence of WTAs (7, 104). This mislocalization correlates with decreased PG cross-linking found in Δ*tarO* mutants (112). In addition, Campbell et al. (25) showed that TarO inhibitors potentiate β-lactams in MRSA strains, indicating a functional connection between the PG and WTA biosynthetic pathways. Farha et al. (48) used a panel of β-lactams to argue that this synthetic lethality was specifically due to combined disruption of the PG cross-linking enzymes PBP2 (via β-lactams) and PBP4 (via WTA biosynthesis inhibition). Although many details remain to be clarified, there is considerable evidence that WTAs regulate the function of PG biosynthetic machinery, and the recruitment of cell wall assembly proteins is one mechanism through which they do so.

#### Regulation of Autolytic Activity

The failure of mutants to effectively septate and separate during cell division implicates WTAs in coordinating the localization, stability, and/or activity of PG lytic proteins. Strains lacking WTAs have altered endogenous autolysin expression profiles and increased autolysis rates (18, 79, 112, 134). In vitro studies performed with purified LTAs, enzymes, and cell wall substrates explain these observations using a recruitment model, in which polyanionic phosphate backbones bind and sequester positively charged autolysins (17, 49, 91). Positively charged D-alanyl esters help mask this charge and free autolysins to degrade PG. This model requires WTAs to be either absent from the septum or present in a highly D-alanylated state, as autolytic activity must be
regulated to ensure separation specifically at the cross wall during cell division (146). Recent studies support an exclusion model (52, 112). Finally, others have proposed that WTAs could indirectly modulate enzyme activity through ion chelation (8, 18, 60). Whether directly or indirectly, or by recruitment or exclusion, WTAs clearly play a role in the localization of autolytic enzymes (52, 104, 112).

**Regulation of Ion Homeostasis**

It is thought that WTAs can bind extracellular metal cations by extending beyond the PG layer (67, 140). WTAs have a high affinity for metals, and their biosynthesis is upregulated under metal limitation (8, 45). WTAs also bind protons, and cells lacking WTAs have a 23% decrease in their proton binding capacity (18). Although WTAs do not influence the pH gradient across the cell wall, it has been suggested that they can create localized changes in pH, indirectly modulating the function of some enzymes (e.g., autolysins) (18). WTA ion binding is also thought to minimize repulsion between nearby phosphate groups, which can affect polymer structure and therefore cell wall integrity (67, 140). D-Alanylation masks negatively charged sites on the polymer, reducing WTAs’ binding capacity for cations (60). Some have also speculated that ion binding to WTAs could help prevent fluctuations in osmotic pressure between the inside and the outside of the cell (4, 60, 120).

**Protection from Host Defenses and Antibiotics**

WTAs and their attached substituents contribute to bacterial cell surface charge and hydrophobicity, which in turn affect binding of extracellular molecules. By affecting cell surface characteristics, WTAs therefore play a role in protecting bacteria from various threats and adverse conditions. In the absence of WTAs, bacteria are sensitive to high temperatures and unable to grow in high-salt media, indicating that WTAs are involved in temperature tolerance and osmotic stress (7, 61, 117, 127). WTA-deficient cells are more susceptible to human antibacterial fatty acids, presumably because hydrophobic antibacterial fatty acids penetrate the less hydrophilic mutant cell wall more easily and bind more efficiently to the cell membrane, where they can cause damage (70).

Preventing D-alanylation through gene deletion removes D-alanine esters from both LTAs and WTAs; consequently, researchers have not yet been able to identify roles specific to each polymer. Nevertheless, it has been established that teichoic acid D-alanylation protects against host-defense mechanisms (73, 74). *S. aureus* lacking D-alanine has an increased susceptibility to phagocytes, to neutrophil killing (32), and to lysostaphin and lysozyme (100). A reduction in the D-alanyl content of the cell wall results in increased susceptibility to glycopeptide antibiotics and to certain cationic antimicrobial peptides (CAMPs) (32, 99, 100, 126, 131). It was reasoned that the absence of D-alanyl esters increases the overall negative cell surface charge (126), attracting cationic molecules and thus increasing susceptibility to CAMPs. Accordingly, *B. subtilis* and *S. aureus* lacking teichoic acid D-alanine modifications bind more positively charged cytochrome *c* than their wild-type counterparts do (99, 134). In group B streptococci, however, D-alanylation shows little influence on the surface association of fluorescently labeled CAMPs (108). These data suggest that charge effects are not solely responsible for the observed changes in CAMP susceptibility. Saar-Dover et al. (108) suggested that the increased cell wall density observed in strains with D-alanylation prevents penetration of CAMPs, thereby conferring protection.

Blocking WTA synthesis renders *B. subtilis* and MRSA sensitive to β-lactam antibiotics (23, 25, 48, 79, 99, 119, 134). Recent studies have replicated this sensitivity through the specific removal of WTA β-GlcNAc modifications (23). It has been speculated that the WTA β-GlcNAc moieties

**Autolysins:** bacterial enzymes that hydrolyze peptidoglycan during cell growth and division; enable incorporation of new material into the cell wall and promote cell separation

scaffold proteins involved in resistance. Accordingly, recent work has shown that *S. aureus* WTAs specifically interact with PBP2A (104), the resistant transpeptidase found in MRSA. Because WTA glycosyl substituents are also receptors for phage (10, 143), there is a precedent for WTA sugar residues mediating protein binding. It is possible that glycosylated WTAs function as ligands for cell surface proteins with carbohydrate recognition sites.

**Effects on Adhesion and Colonization**

The presence of WTAs and their D-alanyl esters influences bacterial interactions with various surfaces (91). WTA-deficient cells have a reduced capability to form biofilms (55, 61, 127, 131). Removal of D-alanine esters also decreases biofilm formation and bacterial adhesion to plastic and glass surfaces. Decreased adherence is potentially linked to the resultant increase in negative cell surface charge creating increased repulsive forces between bacteria and a stratum (55, 61).

In 1980, Aly et al. (2) showed a 71% reduction of *S. aureus* binding to nasal epithelial cells that were preincubated with teichoic acid. Since that time, several animal studies have established that bacteria lacking teichoic acid D-alanine esters or WTAs are attenuated in host colonization and infection (32, 48, 73, 118, 119, 131, 132, 135, 136, 139). Lactobacilli lacking teichoic acid D-alanylation colonize mice gastrointestinal tracts at 1% of wild-type levels (131). Similarly, WTA-free *S. aureus* cells colonize rat nares at levels 90% lower than those of wild-type *S. aureus*, and in rabbits these mutant cells were unable to proliferate to adjacent organs (135, 139). Teichoic acid D-alanine esters are considered virulence factors, because their deletion attenuates pathogenicity but does not cause major cellular defects under laboratory growth conditions (4, 14, 25, 27, 31). WTAs have also been categorized as virulence factors, although they exhibit such profound defects in vitro that they may be better described as “in vivo essential” (30, 138). The decreased ability of WTA null mutants to survive in challenging host environments is due to the combined effects of an inability to adhere to host tissue, an increased susceptibility to host defenses, and cell division defects (74, 91, 131, 137).

**THE WALL TEICHOIC ACID PATHWAY AS AN ANTIBIOTIC TARGET**

The vital roles of WTAs in physiology and pathogenesis promote this pathway as a target for antibacterial drugs and vaccines (120, 137). The WTA pathway contains three distinct target categories: antivirulence targets, β-lactam potentiator targets, and essential targets (Figure 6).

**Antivirulence Targets**

Proponents of virulence factors as antibacterial targets argue that resistance to virulence factor inhibitors is less likely to emerge, because there is no selection pressure for survival (30). Although some argue that these inhibitors are unable to cure established infections and may create unforeseen in vivo host selection pressures, it is nonetheless worth investigating virulence factor targets, particularly for resistant pathogens. Enzymes of the *dlt* operon are targets for antivirulence agents because strains lacking teichoic acid D-alanine esters are strongly attenuated in animal infection models but show minimal growth defects under laboratory growth conditions (137). A DltA inhibitor was reported in 2005 but was not further optimized and is likely not specific (84). The enzymes involved in initiating WTA polymer synthesis, TarO and TarA, have also been described as virulence factor targets, but as noted above, these deletion strains are more than attenuated in animal hosts: They are nonviable (135). Hence, inhibitors of these initiating enzymes may behave more like traditional antibiotics in vivo, although this remains to be established.

MI67CH15-Walker ARI 5 August 2013 17:19

![Diagram](attachment:diagram.png)

Figure 6

WTA biosynthetic enzymes are potential antibiotic targets. The schematic shows the three types of antibacterial targets present in the *Staphylococcus aureus* WTA pathway. Enzymes that are traditional antibiotic targets (*tan*), β-lactam potentiators (*blue*), or antivirulence antimicrobial targets (*green*) are boxed. The three chemical structures illustrated are small molecules known to inhibit the WTA enzymes TarO, TarG, and DltA. Abbreviations: GlcNAc, N-acetylglucosamine; ManNAc, N-acetylmannosamine; TFA, trifluoroacetic acid; WTA, wall teichoic acid.

natural product tunicamycin inhibits TarO at very low concentrations (25, 57, 101), but at higher concentrations it also blocks MraY, an essential UDP-MurNAc-pentapeptide transferase involved in PG biosynthesis (103). Tunicamycin has been used to probe the effects of inhibiting WTA biosynthesis in bacteria; unfortunately, however, it cannot be used in animals because it inhibits GPT, an essential phosphotransferase involved in eukaryotic N-linked glycan biosynthesis (103). Hence, there is still a need for specific nontoxic inhibitors that target TarO, TarA, and Dlt enzymes for use in infection models.
$\beta$-Lactam Potentiator Targets

$\beta$-Lactams are one of the safest and most widely used classes of antibiotics (53), and there is considerable interest in compounds that restore $\beta$-lactam sensitivity to resistant microorganisms. $\beta$-Lactamase inhibitors, for example, have been highly successful as components of compound combinations to treat many $\beta$-lactam-resistant infections (53). $\beta$-Lactam resistance in MRSA is not mediated by $\beta$-lactamases but by the resistant transpeptidase PBP2A (149). Because the activity of this transpeptidase depends on the function of various host factors, compound combinations are possible as therapeutic modalities (149). TarO, TarA, and TarS are $\beta$-lactam potentiator targets. Unlike $\Delta tarO$ and $\Delta tarA$ strains, $\Delta tarS$ mutants divide normally and do not show appreciable growth defects (23). Furthermore, they are not strongly attenuated in virulence. Hence, TarS inhibitors should act exclusively as potentiators, whereas inhibitors of TarO and TarA would serve as both $\beta$-lactam potentiators and antivirulence agents. A cell-based high-throughput $\beta$-lactam potentiation screen recently identified the clinically used antiplatelet drug ticlopidine as a TarO inhibitor, although target selectivity was not demonstrated (48). It should also be possible to identify TarS inhibitors from $\beta$-lactam potentiation screens, as they can be readily discriminated from TarO or TarA inhibitors on the basis of their cellular effects (23).

### Traditional Antibiotic Targets

Inhibitors of the essential late-stage WTA biosynthetic enzymes TarB through TarH should have lethal effects on bacterial cells and thus would be akin to traditional antibiotics. Late-stage WTA pathway inhibitors (e.g., targocil) were discovered by screening a $\Delta tarO$ mutant and a wild-type strain against the same library to identify compounds that selectively killed the wild-type strain. All identified compounds inhibited TarG (77, 121, 132). The identification of several different inhibitors of TarG indicates that this may be a druggable target. This may indicate that WTA precursor export is the rate-limiting step in the pathway, and TarG may also be more accessible to inhibitors than are most other WTA targets because it spans the membrane. All identified TarG inhibitors suffer from a relatively high frequency of resistance (26, 132). Consequently, in an MRSA infection model, the TarG inhibitors were effective only in combination with $\beta$-lactams (132). It would be desirable to identify compounds with a lower frequency of resistance to validate late-stage enzymes as targets independent of $\beta$-lactams.

### CONCLUSION

WTAs compose a huge percentage of the gram-positive cell wall and are thus extremely important for cell wall integrity. They are important for pathogenesis and play fundamental roles in bacterial physiology. Furthermore, their tailoring modifications modulate their structures and interactions with other molecules and cells in complex ways. The variety of enzyme classes involved in WTA biosynthesis (glycosyltransferases, polymerases, ABC transporters) and the diverse functions of WTAs make the ongoing study of this pathway challenging. Small-molecule inhibitors of WTA enzymes can be used to probe enzyme mechanism and WTA function in cells and to explore the potential of the different antibacterial target types.

#### SUMMARY POINTS

1. WTAs are covalently attached to PG and compose up to 60% of the cell wall mass in gram-positive bacteria.
2. The first three steps in WTA biosynthesis, catalyzed by TagO, TagA, and TagB, lead to the formation of a lipid-anchored disaccharide glycerol 3-phosphate and are conserved across many gram-positive bacteria.

3. Cells lacking WTAs have gross defects in cell division and cell morphology. This and other evidence indicate that the WTA and PG biosynthetic pathways are connected.

4. How WTAs function to regulate normal cell physiology is still unclear. They are thought to scaffold some cell wall assembly proteins, to exclude other such proteins, and to influence protein activity through ion chelation.

5. WTAs are required for survival in a host.

6. WTA tailoring modifications are involved in biofilm formation, virulence, and antimicrobial resistance.

7. The WTA pathway is a possible target for β-lactam potentiators, antivirulence agents, and other novel antibiotics.


### FUTURE ISSUES

1. Although most of the steps in WTA biosynthesis have been elucidated, major questions remain regarding the mechanisms of polymer export and attachment to PG.

2. The pathway for D-alanylation of teichoic acids is poorly understood. In particular, the enzymatic functions of DltB and DltD are unknown.

3. There is a long-standing controversy regarding whether WTA precursors are attached to old or new PG. This issue has a direct bearing on how WTAs may regulate PG biosynthesis and cell division.

4. The roles of distinct tailoring modifications in modulating WTA function remain unclear. Glycosylated WTAs are required to maintain β-lactam resistance in MRSA, but a molecular mechanism to explain this observation is lacking.

5. Although small molecules that inhibit WTA synthesis have been identified, and some have been shown to have efficacy in animal models, the WTA pathway as a therapeutic target has yet to be validated.


### DISCLOSURE STATEMENT

The authors are not aware of any affiliations, memberships, funding, or financial holdings that might be perceived as affecting the objectivity of this review.


### ACKNOWLEDGMENTS

The current address for Dr. Stephanie Brown is Department of Biological Chemistry, John Innes Center, Norwich NR4 7UH, United Kingdom.

LITERATURE CITED

1. Allison SE, D'Elia MA, Arar S, Monteiro MA, Brown ED. 2011. Studies of the genetics, function, and kinetic mechanism of TagE, the wall teichoic acid glycosyltransferase in *Bacillus subtilis* 168. *J. Biol. Chem.* 286:23708–16
2. Aly R, Shinefield HR, Litz C, Maibach HI. 1980. Role of teichoic acid in the binding of *Staphylococcus aureus* to nasal epithelial cells. *J. Infect. Dis.* 141:463–65
3. Anderson AJ, Green RS, Sturman AJ, Archibald AR. 1978. Cell wall assembly in *Bacillus subtilis*: location of wall material incorporated during pulsed release of phosphate limitation, its accessibility to bacteriophages and concanavalin A, and its susceptibility to turnover. *J. Bacteriol.* 136:886–99
4. Andre G, Deghorain M, Bron PA, van Swam II, Kleerebezem M, et al. 2011. Fluorescence and atomic force microscopy imaging of wall teichoic acids in *Lactobacillus plantarum*. *ACS Chem. Biol.* 6:366–76
5. Araki Y, Ito E. 1989. Linkage units in cell walls of gram-positive bacteria. *Crit. Rev. Microbiol.* 17:121–35
6. Armstrong JJ, Baddiley J, Buchanan JG, Carss B, Greenberg GR. 1958. Isolation and structure of ribitol phosphate derivatives (teichoic acids) from bacterial cell walls. *J. Chem. Soc.* 1958:4344–54
7. Shows that *S. aureus* WTAs are required for proper localization of PBP4.
8. Atilano ML, Pereira PM, Yates J, Reed P, Veiga H, et al. 2010. Teichoic acids are temporal and spatial regulators of peptidoglycan cross-linking in *Staphylococcus aureus*. *Proc. Natl. Acad. Sci. USA* 107:18991–96
9. Baddiley J. 1970. Structure, biosynthesis, and function of teichoic acids. *Acc. Chem. Res.* 3:98–105
10. Badurina DS, Zolli-Juran M, Brown ED. 2003. CTP:glycerol 3-phosphate cytidylyltransferase (TarD) from *Staphylococcus aureus* catalyzes the cytidylyl transfer via an ordered Bi-Bi reaction mechanism with micromolar \(K_m\) values. *Biochim. Biophys. Acta* 1646:196–206
11. Baptista C, Santos MA, São-José C. 2008. Phage SPP1 reversible adsorption to *Bacillus subtilis* cell wall teichoic acids accelerates virus recognition of membrane receptor YueB. *J. Bacteriol.* 190:4989–96
12. Baur S, Marles-Wright J, Buckenmaier S, Lewis RJ, Vollmer W. 2009. Synthesis of CDP-activated ribitol for teichoic acid precursors in *Streptococcus pneumoniae*. *J. Bacteriol.* 191:1200–10
13. Bera A, Biswas R, Herbert S, Kulauzovic E, Weidenmaier C, et al. 2007. Influence of wall teichoic acid on lysozyme resistance in *Staphylococcus aureus*. *J. Bacteriol.* 189:280–83
14. Bernal P, Zloh M, Taylor PW. 2009. Disruption of D-alanyl esterification of *Staphylococcus aureus* cell wall teichoic acid by the β-lactam resistance modifier (−)-epicatechin gallate. *J. Antimicrob. Chemother.* 63:1156–62
15. Bhavsar AP, Beveridge TJ, Brown ED. 2001. Precise deletion of *tagD* and controlled depletion of its product, glycerol 3-phosphate cytidylyltransferase, leads to irregular morphology and lysis of *Bacillus subtilis* grown at physiological temperature. *J. Bacteriol.* 183:6688–93
16. Bhavsar AP, Erdman LK, Schertzer JW, Brown ED. 2004. Teichoic acid is an essential polymer in *Bacillus subtilis* that is functionally distinct from teichuronic acid. *J. Bacteriol.* 186:7865–73
17. Bhavsar AP, Truant R, Brown ED. 2005. The TagB protein in *Bacillus subtilis* 168 is an intracellular peripheral membrane protein that can incorporate glycerol phosphate onto a membrane-bound acceptor in vitro. *J. Biol. Chem.* 280:36691–700
18. Bierbaum G, Sahl HG. 1985. Induction of autolysis of staphylococci by the basic peptide antibiotics Pep 5 and nisin and their influence on the activity of autolytic enzymes. *Arch. Microbiol.* 141:249–54
19. Biswas R, Martinez RE, Gohring N, Schlag M, Josten M, et al. 2012. Proton-binding capacity of *Staphylococcus aureus* wall teichoic acid and its role in controlling autolysin activity. *PLoS ONE* 7:e41415
20. Boylan RJ, Mendelson NH, Brooks D, Young FE. 1972. Regulation of the bacterial cell wall: analysis of a mutant of *Bacillus subtilis* defective in biosynthesis of teichoic acid. *J. Bacteriol.* 110:281–90
21. Bracha R, Davidson R, Mirelman D. 1978. Defect in biosynthesis of the linkage unit between peptidoglycan and teichoic acid in a bacteriophage-resistant mutant of *Staphylococcus aureus*. *J. Bacteriol.* 134:412–17
22. Bron PA, Tomita S, van Swam II, Remus DM, Meijerink M, et al. 2012. *Lactobacillus plantarum* possesses the capability for wall teichoic acid backbone alditol switching. *Microb. Cell Fact.* 11:123
23. Brown S, Meredith T, Swoboda J, Walker S. 2010. *Staphylococcus aureus* and *Bacillus subtilis* W23 make polyribitol wall teichoic acids using different enzymatic pathways. *Chem. Biol.* 17:1101–10

23. Brown S, Xia G, Luhachack LG, Campbell J, Meredith TC, et al. 2012. Methicillin resistance in *Staphylococcus aureus* requires glycosylated wall teichoic acids. *Proc. Natl. Acad. Sci. USA* 109:18909–14

24. Brown S, Zhang Y-H, Walker S. 2008. A revised pathway proposed for *Staphylococcus aureus* wall teichoic acid biosynthesis based on *in vitro* reconstitution of the intracellular steps. *Chem. Biol.* 15:12–21

25. Campbell J, Singh AK, Santa Maria JP Jr, Kim Y, Brown S, et al. 2011. Synthetic lethal compound combinations reveal a fundamental connection between wall teichoic acid and peptidoglycan biosyntheses in *Staphylococcus aureus*. *ACS Chem. Biol.* 6:106–16

26. Campbell J, Singh AK, Swoboda JG, Gilmore MS, Wilkinson BJ, Walker S. 2012. An antibiotic that inhibits a late step in wall teichoic acid biosynthesis induces the cell wall stress stimulon in *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* 56:1810–20

27. Chatterjee AN, Mirelman D, Singer HJ, Park JT. 1969. Properties of a novel pleiotropic bacteriophage-resistant mutant of *Staphylococcus aureus* H. *J. Bacteriol.* 100:846–53

28. Childs WC III, Taron DJ, Neuhaus FC. 1985. Biosynthesis of D-alanyl-lipoteichoic acid by *Lactobacillus casei*: interchain transacylation of D-alanyl ester residues. *J. Bacteriol.* 162:1191–95

29. Chin T, Burger MM, Glaser L. 1966. Synthesis of teichoic acids. VI. The formation of multiple wall polymers in *Bacillus subtilis* W-23. *Arch. Biochem. Biophys.* 116:358–67

30. Clatworthy AE, Pierson E, Hung DT. 2007. Targeting virulence: a new paradigm for antimicrobial therapy. *Nat. Chem. Biol.* 3:541–48

31. Cole RM, Popkin TJ, Boylan RJ, Mendelson NH. 1970. Ultrastructure of a temperature-sensitive *rod−* mutant of *Bacillus subtilis*. *J. Bacteriol.* 103:793–810

32. Collins LV, Kristian SA, Weidenmaier C, Faigle M, Van Kessel KPM, et al. 2002. *Staphylococcus aureus* strains lacking D-alanine modifications of teichoic acids are highly susceptible to human neutrophil killing and are virulence attenuated in mice. *J. Infect. Dis.* 186:214–19

33. Davison AL, Baddiley J. 1964. Teichoic acids in the walls of *Staphylococci*: glycerol teichoic acids in walls of *Staphylococcus epidermidis*. *Nature* 202:874

34. Debabov DV, Kiriukhin MY, Neuhaus FC. 2000. Biosynthesis of lipoteichoic acid in *Lactobacillus rhamnosus*: role of DltD in D-alanylation. *J. Bacteriol.* 182:2855–64

35. D’Elia MA, Henderson JA, Beveridge TJ, Heinrichs DE, Brown ED. 2009. The N-acetylmannosamine transferase catalyzes the first committed step of teichoic acid assembly in *Bacillus subtilis* and *Staphylococcus aureus*. *J. Bacteriol.* 191:4030–34

36. D’Elia MA, Millar KE, Beveridge TJ, Brown ED. 2006. Wall teichoic acid polymers are dispensable for cell viability in *Bacillus subtilis*. *J. Bacteriol.* 188:8313–16

37. D’Elia MA, Millar KE, Bhavsar AP, Tomljenovic AM, Hutter B, et al. 2009. Probing teichoic acid genetics with bioactive molecules reveals new interactions among diverse processes in bacterial cell wall biogenesis. *Chem. Biol.* 16:548–56

38. D’Elia MA, Pereira MP, Chung YS, Zhao W, Chau A, et al. 2006. Lesions in teichoic acid biosynthesis in *Staphylococcus aureus* lead to a lethal gain of function in the otherwise dispensable pathway. *J. Bacteriol.* 188:4183–89

39. Denapaite D, Bruckner R, Hakenbeck R, Vollmer W. 2012. Biosynthesis of teichoic acids in *Streptococcus pneumoniae* and closely related species: lessons from genomes. *Microb. Drug Resist.* 18:344–58

40. Dengler V, Meier PS, Heusser R, Kupferschmied P, Fazekas J, et al. 2012. Deletion of hypothetical wall teichoic acid ligases in *Staphylococcus aureus* activates the cell wall stress response. *FEMS Microbiol. Lett.* 333:109–20

41. Dreisbach A, van Dijl JM, Buist G. 2011. The cell surface proteome of *Staphylococcus aureus*. *Proteomics* 11:3154–68

42. Eberhardt A, Hoyland CN, Vollmer D, Bisle S, Cleverley RM, et al. 2012. Attachment of capsular polysaccharide to the cell wall in *Streptococcus pneumoniae*. *Microb. Drug Resist.* 18:240–55

43. Elbaz M, Ben-Yehuda S. 2010. The metabolic enzyme ManA reveals a link between cell wall integrity and chromosome morphology. *PLoS Genet.* 6:e1001119

44. Ellwood DC. 1970. The wall content and composition of *Bacillus subtilis* var. *niger* grown in a chemostat. *Biochem. J.* 118:367–73

45. Endl J, Seidl HP, Fiedler F, Schleifer KH. 1983. Chemical composition and structure of cell wall teichoic acids of staphylococci. *Arch. Microbiol.* 135:215–23

46. Endl J, Seidl PH, Fiedler F, Schleifer KH. 1984. Determination of cell wall teichoic acid structure of staphylococci by rapid chemical and serological screening methods. *Arch. Microbiol.* 137:272–80

47. Eugster MR, Loessner MJ. 2012. Wall teichoic acids restrict access of bacteriophage endolysin Ply118, Ply511, and PlyP40 cell wall binding domains to the *Listeria monocytogenes* peptidoglycan. *J. Bacteriol.* 194:6498–506

48. Farha MA, Leung A, Sewell EW, D'Elia MA, Allison SE, et al. 2013. Inhibition of WTA synthesis blocks the cooperative action of PBPs and sensitizes MRSA to β-lactams. *ACS Chem. Biol.* 8:226–33

49. Fischer W, Rosel P, Koch HU. 1981. Effect of alanine ester substitution and other structural features of lipoteichoic acids on their inhibitory activity against autolysins of *Staphylococcus aureus*. *J. Bacteriol.* 146:467–75

50. Fitzgerald SN, Foster TJ. 2000. Molecular analysis of the *tagF* gene, encoding CDP-glycerol:poly(glycerophosphate) glycerolphosphotransferase of *Staphylococcus epidermidis* ATCC 14990. *J. Bacteriol.* 182:1046–52

51. Formstone A, Carballido-López R, Noirot P, Errington J, Scheffers D-J. 2008. Localization and interactions of teichoic acid synthetic enzymes in *Bacillus subtilis*. *J. Bacteriol.* 190:1812–21

52. Frankel MB, Schneewind O. 2012. Determinants of murein hydrolase targeting to cross-wall of *Staphylococcus aureus* peptidoglycan. *J. Biol. Chem.* 287:10460–71

53. Geddes AM, Klugman KP, Rolinson GN. 2007. Introduction: historical perspective and development of amoxicillin/clavulanate. *Int. J. Antimicrob. Agents* 30(Suppl. 2):S109–12

54. Ginsberg C, Zhang Y-H, Yuan Y, Walker S. 2006. *In vitro* reconstitution of two essential steps in wall teichoic acid biosynthesis. *ACS Chem. Biol.* 1:25–28

55. Gross M, Cramton SE, Götz F, Peschel A. 2001. Key role of teichoic acid net charge in *Staphylococcus aureus* colonization of artificial surfaces. *Infect. Immun.* 69:3423–26

56. Haas R, Koch HU, Fischer W. 1984. Alanyl turnover from lipoteichoic acid to teichoic acid in *Staphylococcus aureus*. *FEMS Microbiol. Lett.* 21:27–31

57. Hancock I, Wiseman G, Baddiley J. 1976. Biosynthesis of the unit that links teichoic acid to the bacterial wall: inhibition by tunicamycin. *FEBS Lett.* 69:75–80

58. Heaton MP, Neuhaus FC. 1992. Biosynthesis of D-alanyl-lipoteichoic acid: cloning, nucleotide sequence, and expression of the *Lactobacillus casei* gene for the D-alanine-activating enzyme. *J. Bacteriol.* 174:4707–17

59. Heaton MP, Neuhaus FC. 1994. Role of the D-alanyl carrier protein in the biosynthesis of D-alanyl-lipoteichoic acid. *J. Bacteriol.* 176:681–90

60. Heptinstall S, Archibald AR, Baddiley J. 1970. Teichoic acids and membrane function in bacteria. *Nature* 225:519–21

61. Holland L, Conlon B, O’Gara JP. 2010. Mutation of *tagO* reveals an essential role for wall teichoic acids in *Staphylococcus epidermidis* biofilm development. *Microbiology* 157:408–18

62. Hubscher J, McCallum N, Sifri CD, Majcherczyk PA, Entenza JM, et al. 2009. MsrR contributes to cell surface characteristics and virulence in *Staphylococcus aureus*. *FEMS Microbiol. Lett.* 295:251–60

63. James DB, Yother J. 2012. Genetic and biochemical characterizations of enzymes involved in *Streptococcus pneumoniae* serotype 2 capsule synthesis demonstrate that Cps2T (WchF) catalyzes the committed step by addition of β1–4 rhamnose, the second sugar residue in the repeat unit. *J. Bacteriol.* 194:6479–89

64. Jenni R, Berger-Bächi B. 1998. Teichoic acid content in different lineages of *Staphylococcus aureus* NCTC8325. *Arch. Microbiol.* 170:171–78

65. Karamata D, Pooley HM, Monod M. 1987. Expression of heterologous genes for wall teichoic acid in *Bacillus subtilis* 168. *Mol. Gen. Genet.* 207:73–81

66. Identification and crystallization of the potential WTA ligases.

66. Kawai Y, Marles-Wright J, Cleverley RM, Emmins R, Ishikawa S, et al. 2011. A widespread family of bacterial cell wall assembly proteins. *EMBO J.* 30:4931–41

67. Kern T, Giffard M, Hediger S, Amoroso A, Giustini C, et al. 2010. Dynamics characterization of fully hydrated bacterial cell walls by solid-state NMR: evidence for cooperative binding of metal ions. *J. Am. Chem. Soc.* 132:10911–19

68. Kiriukhin MY, Neuhaus FC. 2001. D-alanylation of lipoteichoic acid: role of the D-alanyl carrier protein in acylation. *J. Bacteriol.* 183:2051–58

69. Kobayashi K, Ehrlich SD, Albertini A, Amati G, Andersen KK, et al. 2003. Essential *Bacillus subtilis* genes. *Proc. Natl. Acad. Sci. USA* 100:4678–83

70. Kohler T, Weidenmaier C, Peschel A. 2009. Wall teichoic acid protects *Staphylococcus aureus* against antimicrobial fatty acids from human skin. *J. Bacteriol.* 191:4482–84

71. Kojima N, Araki Y, Ito E. 1985. Structure of the linkage units between ribitol teichoic acids and peptidoglycan. *J. Bacteriol.* 161:299–306

72. Kovács M, Halfmann A, Fedtke I, Heintz M, Peschel A, et al. 2006. A functional *dlt* operon, encoding proteins required for incorporation of D-alanine in teichoic acids in gram-positive bacteria, confers resistance to cationic antimicrobial peptides in *Streptococcus pneumoniae*. *J. Bacteriol.* 188:5797–805

73. Kristian SA, Datta V, Weidenmaier C, Kansal R, Fedtke I, et al. 2005. D-alanylation of teichoic acids promotes group A streptococcus antimicrobial peptide resistance, neutrophil survival, and epithelial cell invasion. *J. Bacteriol.* 187:6719–25

74. Kristian SA, Lauth X, Nizet V, Goetz F, Neumeister B, et al. 2003. Alanylation of teichoic acids protects *Staphylococcus aureus* against Toll-like receptor 2-dependent host defense in a mouse tissue cage infection model. *J. Infect. Dis.* 188:414–23

75. Lazarevic V, Abellan F-X, Möller SB, Karamata D, Mauël C. 2002. Comparison of ribitol and glycerol teichoic acid genes in *Bacillus subtilis* W23 and 168: identical function, similar divergent organization, but different regulation. *Microbiology* 148:815–24

76. Lazarevic V, Karamata D. 1995. The *tagGH* operon of *Bacillus subtilis* 168 encodes a two-component ABC transporter involved in the metabolism of two wall teichoic acids. *Mol. Microbiol.* 16:345–55

77. Lee K, Campbell J, Swoboda JG, Cuny GD, Walker S. 2010. Development of improved inhibitors of wall teichoic acid biosynthesis with potent activity against *Staphylococcus aureus*. *Bioorg. Med. Chem. Lett.* 20:1767–70

78. Lovering AL, Lin LY-C, Sewell EW, Spreter T, Brown ED, Strynadka NCJ. 2010. Structure of the bacterial teichoic acid polymerase TagF provides insights into membrane association and catalysis. *Nat. Struct. Mol. Biol.* 17:582–89

79. Maki H, Yamaguchi T, Murakami K. 1994. Cloning and characterization of a gene affecting the methicillin resistance level and the autolysis rate in *Staphylococcus aureus*. *J. Bacteriol.* 176:4993–5000

80. Matias VR, Beveridge TJ. 2005. Cryo-electron microscopy reveals native polymeric cell wall structure in *Bacillus subtilis* 168 and the existence of a periplasmic space. *Mol. Microbiol.* 56:240–51

81. Matias VR, Beveridge TJ. 2006. Native cell wall organization shown by cryo-electron microscopy confirms the existence of a periplasmic space in *Staphylococcus aureus*. *J. Bacteriol.* 188:1011–21

82. Matias VR, Beveridge TJ. 2007. Cryo-electron microscopy of cell division in *Staphylococcus aureus* reveals a mid-zone between nascent cross walls. *Mol. Microbiol.* 64:195–206

83. Mauck J, Glaser L. 1972. On the mode of *in vivo* assembly of the cell wall of *Bacillus subtilis*. *J. Biol. Chem.* 247:1180–87

84. May JJ, Finking R, Wiegeshoff F, Weber TT, Bandur N, et al. 2005. Inhibition of the D-alanine:D-alanyl carrier protein ligase from *Bacillus subtilis* increases the bacterium’s susceptibility to antibiotics that target the cell wall. *FEBS J.* 272:2993–3003

85. Meredith TC, Swoboda JG, Walker S. 2008. Late-stage polyribitol phosphate wall teichoic acid biosynthesis in *Staphylococcus aureus*. *J. Bacteriol.* 190:3046–56

86. Mericl AN, Friesen JA. 2012. Comparative kinetic analysis of glycerol 3-phosphate cytidylyltransferase from *Enterococcus faecalis* and *Listeria monocytogenes*. *Med. Sci. Monit.* 18:427–34

87. Minnig K, Lazarevic V, Soldo B, Mauël C. 2005. Analysis of teichoic acid biosynthesis regulation reveals that the extracytoplasmic function sigma factor σ<sup>M</sup> is induced by phosphate depletion in *Bacillus subtilis* W23. *Microbiology* 151:3041–49

88. Nathenson SG, Ishimoto N, Anderson JS, Strominger JL. 1966. Enzymatic synthesis and immunochemistry of α- and β-N-acetylglucosaminylribitol linkages in teichoic acids from several strains of *Staphylococcus aureus*. *J. Biol. Chem.* 241:651–58

89. Naumova IB, Kuznetsov VD, Kudrina KS, Bezzubenkova AP. 1980. The occurrence of teichoic acids in streptomycetes. *Arch. Microbiol.* 126:71–75

90. Naumova IB, Shashkov AS, Tul'skaya EM, Streshinskaya GM, Kozlova YI, et al. 2001. Cell wall teichoic acids: structural diversity, species specificity in the genus *Nocardopsis*, and chemotaxonomic perspective. *FEMS Microbiol. Rev.* 25:269–84

91. Neuhaus FC, Baddiley J. 2003. A continuum of anionic charge: structures and functions of D-alanyl-teichoic acids in gram-positive bacteria. *Microbiol. Mol. Biol. Rev.* 67:686–723

92. Over B, Heusser R, McCallum N, Schulthess B, Kupferschmied P, et al. 2011. LytR-CpsA-Psr proteins in *Staphylococcus aureus* display partial functional redundancy and the deletion of all three severely impairs septum placement and cell separation. *FEMS Microbiol. Lett.* 320:142–51

93. Park JT, Shaw DR, Chatterjee AN, Mirelman D, Wu T. 1974. Mutants of staphylococci with altered cell walls. *Ann. N. Y. Acad. Sci.* 236:54–62

94. Park YS, Sweitzer TD, Dixon JE, Kent C. 1993. Expression, purification, and characterization of CTP:glycerol-3-phosphate cytidylyltransferase from *Bacillus subtilis*. *J. Biol. Chem.* 268:16648–54

95. Perego M, Glaser P, Minutello A, Strauch MA, Leopold K, Fischer W. 1995. Incorporation of D-alanine into lipoteichoic acid and wall teichoic acid in *Bacillus subtilis*: identification of genes and regulation. *J. Biol. Chem.* 270:15598–606

96. Pereira MP, Brown ED. 2004. Bifunctional catalysis by CDP-ribitol synthase: convergent recruitment of reductase and cytidylyltransferase activities in *Haemophilus influenzae* and *Staphylococcus aureus*. *Biochemistry* 43:11802–12

97. Pereira MP, D'Elia MA, Troczynska J, Brown ED. 2008. Duplication of teichoic acid biosynthetic genes in *Staphylococcus aureus* leads to functionally redundant poly(ribitol phosphate) polymerases. *J. Bacteriol.* 190:5642–49

98. Pereira MP, Schertzer JW, D'Elia MA, Koteva KP, Hughes DW, et al. 2008. The wall teichoic acid polymerase TagF efficiently synthesizes poly(glycerol phosphate) on the TagB product lipid III. *ChemBioChem* 9:1385–90

99. Peschel A, Otto M, Jack RW, Kalbacher H, Jung G, Götz F. 1999. Inactivation of the *dlt* operon in *Staphylococcus aureus* confers sensitivity to defensins, protegrins, and other antimicrobial peptides. *J. Biol. Chem.* 274:8405–10

100. Peschel A, Vuong C, Otto M, Götz F. 2000. The D-alanine residues of *Staphylococcus aureus* teichoic acids alter the susceptibility to vancomycin and the activity of autolytic enzymes. *Antimicrob. Agents Chemother.* 44:2845–47

101. Pooley HM, Karamata D. 2000. Incorporation of [2-³H] glycerol into cell surface components of *Bacillus subtilis* 168 and thermosensitive mutants affected in wall teichoic acid synthesis: effect of tunicamycin. *Microbiology* 146:797–805

102. Potekhina NV, Streshinskaya GM, Tul'skaya EM, Kozlova YI, Senchenkova SN, Shashkov AS. 2011. Phosphate-containing cell wall polymers of bacilli. *Biochemistry (Moscow)* 76:745–54

103. Price N, Tsvetanova B. 2007. Biosynthesis of the tunicamycins: a review. *J. Antibiot.* 60:485–91

104. Qamar A, Golemi-Kotra D. 2012. Dual roles of FmtA in *Staphylococcus aureus* cell wall biosynthesis and autolysis. *Antimicrob. Agents Chemother.* 56:3797–805

105. Qian Z, Yin Y, Zhang Y, Lu L, Li Y, Jiang Y. 2006. Genomic characterization of ribitol teichoic acid synthesis in *Staphylococcus aureus*: genes, genomic organization and gene duplication. *BMC Genomics* 7:74

106. Reichmann NT, Gründling A. 2011. Location, synthesis and function of glycolipids and polyglycerolphosphate lipoteichoic acid in Gram-positive bacteria of the phylum *Firmicutes*. *FEMS Microbiol. Lett.* 319:97–105

107. Rubinchik E, Schneider T, Elliott M, Scott WR, Pan J, et al. 2011. Mechanism of action and limited cross-resistance of new lipopeptide MX-2401. *Antimicrob. Agents Chemother.* 55:2743–54

108. Saar-Dover R, Bitler A, Nezer R, Shmuel-Galia L, Firon A, et al. 2012. D-alanylation of lipoteichoic acids confers resistance to cationic peptides in group B *Streptococcus* by increasing the cell wall density. *PLoS Pathog.* 8:e1002891

109. Schertzer JW, Brown ED. 2003. Purified, recombinant TagF protein from *Bacillus subtilis* 168 catalyzes the polymerization of glycerol phosphate onto a membrane acceptor in vitro. *J. Biol. Chem.* 278:18002–7

110. Schertzer JW, Brown ED. 2008. Use of CDP-glycerol as an alternate acceptor for the teichoic acid polymerase reveals that membrane association regulates polymer length. *J. Bacteriol.* 190:6940–47

111. Schirner K, Stone LK, Walker S. 2011. ABC transporters required for export of wall teichoic acids do not discriminate between different main chain polymers. *ACS Chem. Biol.* 6:407–12

112. Schlag M, Biswas R, Krismer B, Kohler T, Zoll S, et al. 2010. Role of staphylococcal wall teichoic acid in targeting the major autolysin Atl. *Mol. Microbiol.* 75:864–73

113. Sewell EWC, Pereira MP, Brown ED. 2009. The wall teichoic acid polymerase TagF is non-processive in vitro and amenable to study using steady state kinetic analysis. *J. Biol. Chem.* 284:21132–38

114. Silhavy TJ, Kahne D, Walker S. 2010. The bacterial cell envelope. *Cold Spring Harb. Perspect. Biol.* 2:a000414

115. Smith T, Blackman S, Foster S. 2000. Autolysins of *Bacillus subtilis*: multiple enzymes with multiple functions. *Microbiology* 146:249–62

116. Soldo B, Lazarevic V, Karamata D. 2002. *tagO* is involved in the synthesis of all anionic cell-wall polymers in *Bacillus subtilis* 168. *Microbiology* 148:2079–87

117. Soldo B, Lazarevic V, Pooley HM, Karamata D. 2002. Characterization of a *Bacillus subtilis* thermosensitive teichoic acid-deficient mutant: gene *mnaA (yvyH)* encodes the UDP-N-acetylglucosamine 2-epimerase. *J. Bacteriol.* 184:4316–20

118. Suzuki T, Campbell J, Swoboda JG, Walker S, Gilmore MS. 2011. Role of wall teichoic acids in *Staphylococcus aureus* endophthalmitis. *Investig. Ophthalmol. Vis. Sci.* 52:3187–92

119. Suzuki T, Swoboda JG, Campbell J, Walker S, Gilmore MS. 2011. In vitro antimicrobial activity of wall teichoic acid biosynthesis inhibitors against *Staphylococcus aureus* isolates. *Antimicrob. Agents Chemother.* 55:767–74

120. Swoboda JG, Campbell J, Meredith TC, Walker S. 2010. Wall teichoic acid function, biosynthesis, and inhibition. *ChemBioChem* 11:35–45

121. Swoboda JG, Meredith TC, Campbell J, Brown S, Suzuki T, et al. 2009. Discovery of a small molecule that blocks wall teichoic acid biosynthesis in *Staphylococcus aureus*. *ACS Chem. Biol.* 4:875–83

122. Theilacker C, Holst O, Lindner B, Huebner J, Kaczynski Z. 2012. The structure of the wall teichoic acid isolated from *Enterococcus faecalis* strain 12030. *Carbohydr. Res.* 354:106–9

123. Tomasz A, McDonnell M, Westphal M, Zanati E. 1975. Coordinated incorporation of nascent peptidoglycan and teichoic acid into pneumococcal cell walls and conservation of peptidoglycan during growth. *J. Biol. Chem.* 250:337–41

124. Tomita S, Irisawa T, Tanaka N, Nukada T, Satoh E, et al. 2010. Comparison of components and synthesis genes of cell wall teichoic acid among *Lactobacillus plantarum* strains. *Biosci. Biotechnol. Biochem.* 74:928–33

125. Torii M, Kabat EA, Bezer AE. 1964. Separation of teichoic acid of *Staphylococcus aureus* into two immunologically distinct specific polysaccharides with α- and β-N-acetylglucosaminyl linkages respectively: antigenicity of teichoic acids in man. *J. Exp. Med.* 120:13–29

126. Vadyvaloo V, Arous S, Gravesen A, Héchard Y, Chauhan-Haubrock R, et al. 2004. Cell-surface alterations in class IIa bacteriocin-resistant *Listeria monocytogenes* strains. *Microbiology* 150:3025–33

127. Vergara-Irigaray M, Maira-Litrán T, Merino N, Pier GB, Penadés JR, Lasa I. 2008. Wall teichoic acids are dispensable for anchoring the PNAG exopolysaccharide to the *Staphylococcus aureus* cell surface. *Microbiology* 154:865–77

128. Vinogradov E, Sadovskaya I, Li J, Jabbouri S. 2006. Structural elucidation of the extracellular and cell-wall teichoic acids of *Staphylococcus aureus* MN8m, a biofilm forming strain. *Carbohydr. Res.* 341:738–43

129. Volkman BF, Zhang Q, Debabov DV, Rivera E, Kresheck GC, Neuhaus FC. 2001. Biosynthesis of D-alanyl-lipoteichoic acid: the tertiary structure of apo-D-alanyl carrier protein. *Biochemistry* 40:7964–72

130. Vollmer W, Blanot D, de Pedro MA. 2008. Peptidoglycan structure and architecture. *FEMS Microbiol. Rev.* 32:149–67

131. Walter J, Loach DM, Alqumber M, Rockel C, Hermann C, et al. 2007. D-alanyl ester depletion of teichoic acids in *Lactobacillus reuteri* 100-23 results in impaired colonization of the mouse gastrointestinal tract. *Environ. Microbiol.* 9:1750–60

132. Wang H, Gill CJ, Lee SH, Mann P, Zuck P, et al. 2013. Discovery of wall teichoic acid inhibitors as potential anti-MRSA β-lactam combination agents. *Chem. Biol.* 20:272–84

133. Ward JB. 1981. Teichoic and teichuronic acids: biosynthesis, assembly, and location. *Microbiol. Rev.* 45:211–43

134. Wecke J, Madela K, Fischer W. 1997. The absence of D-alanine from lipoteichoic acid and wall teichoic acid alters surface charge, enhances autolysis and increases susceptibility to methicillin in *Bacillus subtilis*. *Microbiology* 143:2952–60

135. Weidenmaier C, Kokai-Kun JF, Kristian SA, Chanturiya T, Kalbacher H, et al. 2004. Role of teichoic acids in *Staphylococcus aureus* nasal colonization, a major risk factor in nosocomial infections. *Nat. Med.* 10:243–45

136. Weidenmaier C, Kokai-Kun JF, Kulauzovic E, Kohler T, Thumm G, et al. 2008. Differential roles of sortase-anchored surface proteins and wall teichoic acid in *Staphylococcus aureus* nasal colonization. *Int. J. Med. Microbiol.* 298:505–13

137. Weidenmaier C, Kristian SA, Peschel A. 2003. Bacterial resistance to antimicrobial host defenses—an emerging target for novel antiinfective strategies? *Curr. Drug Targets* 4:643–49

138. Weidenmaier C, Peschel A. 2008. Teichoic acids and related cell-wall glycopolymers in Gram-positive physiology and host interactions. *Nat. Rev. Microbiol.* 6:276–87

139. Weidenmaier C, Peschel A, Xiong Y-Q, Kristian SA, Dietz K, et al. 2005. Lack of wall teichoic acids in *Staphylococcus aureus* leads to reduced interactions with endothelial cells and to attenuated virulence in a rabbit model of endocarditis. *J. Infect. Dis.* 191:1771–77

140. Wickham JR, Halye JL, Kashtanov S, Khandogin J, Rice CV. 2009. Revisiting magnesium chelation by teichoic acid with phosphorus solid-state NMR and theoretical calculations. *J. Phys. Chem. B* 113:2177–83

141. Wyke AW, Ward JB. 1977. Biosynthesis of wall polymers in *Bacillus subtilis*. *J. Bacteriol.* 130:1055–63

142. Xayarath B, Yother J. 2007. Mutations blocking side chain assembly, polymerization, or transport of a Wzy-dependent *Streptococcus pneumoniae* capsule are lethal in the absence of suppressor mutations and can affect polymer transfer to the cell wall. *J. Bacteriol.* 189:3369–81

143. Xia G, Corrigan RM, Winstel V, Goerke C, Gründling A, Peschel A. 2011. Wall teichoic acid-dependent adsorption of staphylococcal siphovirus and myovirus. *J. Bacteriol.* 193:4006–9

144. Xia G, Kohler T, Peschel A. 2010. The wall teichoic acid and lipoteichoic acid polymers of *Staphylococcus aureus*. *Int. J. Med. Microbiol.* 300:148–54

145. Xia G, Maier L, Sanchez-Carballo P, Li M, Otto M, et al. 2010. Glycosylation of wall teichoic acid in *Staphylococcus aureus* by TarM. *J. Biol. Chem.* 285:13405–15

146. Yamamoto H, Miyake Y, Hisaoka M, Kurosawa S-I, Sekiguchi J. 2008. The major and minor wall teichoic acids prevent the sidewall localization of vegetative DL-endopeptidase LytF in *Bacillus subtilis*. *Mol. Microbiol.* 70:297–310

147. Yokoyama K, Miyashita T, Araki Y, Ito E. 1986. Structure and functions of linkage unit intermediates in the biosynthesis of ribitol teichoic acids in *Staphylococcus aureus* H and *Bacillus subtilis* W23. *Eur. J. Biochem.* 161:479–89

148. Young M, Mauël C, Margot P, Karamata D. 1989. Pseudo-allelic relationship between non-homologous genes concerned with biosynthesis of polyglycerol phosphate and polyribitol phosphate teichoic acids in *Bacillus subtilis* strains 168 and W23. *Mol. Microbiol.* 3:1805–12

149. Zapun A, Contreras-Martel C, Vernet T. 2008. Penicillin-binding proteins and β-lactam resistance. *FEMS Microbiol. Rev.* 32:361–85

150. Zhang Y-H, Ginsberg C, Yuan Y, Walker S. 2006. Acceptor substrate selectivity and kinetic mechanism of *Bacillus subtilis* TagA. *Biochemistry* 45:10895–904

151. Zolli M, Kobric D, Brown E. 2001. Reduction precedes cytidylyl transfer without substrate channeling in distinct active sites of the bifunctional CDP-ribitol synthase from *Haemophilus influenzae*. *Biochemistry* 40:5041–48

# Contents

Fifty Years Fused to Lac  
*Jonathan Beckwith* . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
The Algal Past and Parasite Present of the Apicoplast  
*Giel G. van Dooren and Boris Striepen* ………………………………………… 271  

Hypoxia and Gene Expression in Eukaryotic Microbes  
*Geraldine Butler* ……………………………………………………………… 291  

Wall Teichoic Acids of Gram-Positive Bacteria  
*Stephanie Brown, John P. Santa Maria Jr., and Suzanne Walker* …………………… 313  

Archaeal Biofilms: The Great Unexplored  
*Alvaro Orell, Sabrina Fröls, and Sonja-Verena Albers* ………………………… 337  

An Inquiry into the Molecular Basis of HSV Latency and Reactivation  
*Bernard Roizman and Richard J. Whitley* ………………………………………… 355  

Molecular Bacteria-Fungi Interactions: Effects on Environment, Food,  
and Medicine  
*Kirstin Scherlach, Katharina Graupner, and Christian Hertweck* ………………… 375  

Fusarium Pathogenomics  
*Li-Jun Ma, David M. Geiser, Robert H. Proctor, Alejandro P. Rooney,*  
*Kerry O'Donnell, Frances Trail, Donald M. Gardiner, John M. Manners,*  
*and Kemal Kazan* ……………………………………………………………… 399  

Biological Consequences and Advantages of Asymmetric  
Bacterial Growth  
*David T. Kysela, Pamela J.B. Brown, Kerwyn Casey Huang, and Yves V. Brun* … 417  

Archaea in Biogeochemical Cycles  
*Pierre Ovre, Anja Spang, and Christa Schleper* ……………………………… 437  

Experimental Approaches for Defining Functional Roles of Microbes  
in the Human Gut  
*Gautam Dantas, Morten O.A. Sommer, Patrick H. Degnan,*  
*and Andrew L. Goodman* ………………………………………………………… 459  

Plant Cell Wall Deconstruction by Ascomycete Fungi  
*N. Louise Glass, Monika Schmoll, Jamie H.D. Cate, and Samuel Coradetti* …… 477  

Cnidarian-Microbe Interactions and the Origin of Innate  
Immunity in Metazoans  
*Thomas C.G. Bosch* ……………………………………………………………… 499  

On the Biological Success of Viruses  
*Brian R. Wasik and Paul E. Turner* …………………………………………… 519  

Prions and the Potential Transmissibility of Protein  
Misfolding Diseases  
*Allison Kraus, Bradley R. Groveman, and Byron Caughey* ……………………… 543  

The Wonderful World of Archaeal Viruses
David Prangishvili ………………………………………… 565

Tip Growth in Filamentous Fungi: A Road Trip to the Apex
Meritxell Riquelme ………………………………………… 587

A Paradigm for Endosymbiotic Life: Cell Differentiation of *Rhizobium* Bacteria Provoked by Host Plant Factors
Eva Kondorosi, Peter Mergaert, and Attila Kereszt ………………………………………… 611

Neutrophils Versus *Staphylococcus aureus*: A Biological Tug of War
András N. Spaan, Bas G.J. Surewaard, Reindert Nijland, and Jos A.G. van Strijp ………………………………………… 629

Index

Cumulative Index of Contributing Authors, Volumes 63–67 ………………………………………… 651

Errata

An online log of corrections to *Annual Review of Microbiology* articles may be found at http://micro.annualreviews.org/
